Adults with mild-to-moderate hearing loss can now turn a pair of $249 AirPods Pro into a federally authorized hearing aid, no prescription or audiologist visit required. The FDA cleared a software device called “Hearing Aid Feature” for use with compatible AirPods Pro models, making it the first over-the-counter hearing aid software the agency has ever authorized. The decision, issued through the De Novo regulatory pathway, collapses the distance between a consumer earbud and a medical device into a single software update.
How a software update turned AirPods Pro into a regulated medical device
The FDA’s authorization is not a general endorsement of consumer earbuds for hearing assistance. It applies specifically to the Hearing Aid Feature software running on compatible AirPods Pro hardware, which the agency described in its press materials as a novel, over-the-counter medical device. The De Novo pathway is reserved for low-to-moderate-risk products that lack a direct predecessor on the market, signaling that regulators treated this as a genuinely new category rather than a variant of existing OTC hearing aids.
That category itself is relatively young. The FDA published the OTC hearing aid rule in the Federal Register on August 17, 2022, and the rule took effect on October 17, 2022. Under that framework, OTC hearing aids are intended for adults 18 and older with perceived mild-to-moderate hearing loss and can be sold without a prescription or professional exam. Apple’s software authorization builds directly on that regulatory foundation, but it is the first time the FDA has cleared a software layer that converts an existing consumer device into a hearing aid rather than authorizing a purpose-built hardware product.
The practical consequence for buyers is straightforward. Someone who already owns AirPods Pro, or who purchases a pair at $249, can activate a hearing aid function without scheduling an appointment, paying for a fitting, or buying a separate device that often costs well over $1,000. That price gap matters because traditional hearing aids have long carried costs that discourage adoption, even among people who know their hearing has declined. For tech-savvy users, the friction is lower still: the same earbuds that handle music, calls, and noise cancellation now double as a medical device with a few taps in a settings menu.
Peer-reviewed accuracy data and what it actually measured
Independent researchers have already tested the AirPods Pro 2 hearing test feature in a peer-reviewed study indexed on PubMed. The study, published in Otolaryngology–Head and Neck Surgery, assessed the feature for accuracy, reliability, and time efficiency when used as a self-administered screening tool. The researchers reported that the built-in hearing test delivered acceptable performance for identifying mild-to-moderate hearing loss in adults, which matters because the test is the gateway to activating the hearing aid function. If the screening is unreliable, users could receive an inaccurate sound profile, undermining the amplification that follows.
The existence of independent validation sets the AirPods hearing feature apart from many OTC hearing aids that entered the market after the 2022 rule took effect. Several of those devices launched with manufacturer claims but limited third-party testing. A peer-reviewed study that confirms screening accuracy gives both consumers and clinicians a concrete reference point, even if the study focused on test performance rather than day-to-day listening quality.
This distinction is worth tracking. A screening tool that reliably identifies mild-to-moderate loss is a necessary first step, but it does not guarantee that the amplification algorithm will match the quality of a professionally fitted device. The FDA’s authorization confirms the software meets safety and effectiveness standards for OTC use, but long-term real-world performance data, including adverse event reports through the agency’s MAUDE database, will take time to accumulate. Clinicians may ultimately look for patterns in those reports-such as discomfort, feedback, or under-amplification-that do not surface in early lab-based evaluations.
Daily retention versus professional audiology referrals
One likely outcome of the AirPods hearing aid feature is that users will wear the device far more consistently than buyers of traditional OTC hearing aids. AirPods already serve as music players, phone headsets, and noise-canceling tools, so adding a hearing aid function to a device people already carry daily removes the stigma and inconvenience that cause many hearing aid owners to leave their devices in a drawer. Higher daily retention could translate into better hearing outcomes simply because the amplification is actually being used during conversations, meetings, and social events.
The flip side is what happens to professional audiology. When a $249 earbud offers a self-administered hearing test and automated sound amplification, the incentive to book an appointment with an audiologist drops. Adults with mild loss who might have been referred to a specialist after a primary care visit now have a consumer-grade alternative that skips that step entirely. Conversion rates to professional audiology services are unlikely to rise and could decline, particularly among younger adults who are comfortable managing health tools through their phones.
That trade-off is not necessarily negative. For the large population of adults who report hearing difficulty but have never sought treatment, any amplification is better than none. The risk is that some users with hearing loss beyond the mild-to-moderate range will rely on AirPods instead of seeking a clinical evaluation that could identify treatable conditions such as impacted earwax, otosclerosis, or acoustic neuroma. The FDA’s OTC framework explicitly limits these devices to perceived mild-to-moderate loss, but the line between “perceived” and “actual” severity is easy to blur when the only assessment is a quick app-based test.
Responsible deployment will likely depend on how prominently Apple and retailers communicate those limits. Clear in-app warnings about red-flag symptoms-such as sudden hearing loss, unilateral tinnitus, or ear pain-could nudge users toward medical care when software alone is not appropriate. Primary care physicians and audiologists, in turn, may start treating AirPods-based screening results as a conversation starter rather than a replacement for formal audiometry, using them to triage which patients most urgently need a full workup.
What this means for the hearing aid market
Apple’s entry into regulated hearing technology is poised to reshape expectations across the category. For incumbents, the competitive pressure is not just about price; it is about usability and integration. A hearing aid that lives inside a popular consumer gadget, updates over the air, and syncs seamlessly with a smartphone ecosystem reframes what users think a medical device should feel like. Established hearing aid manufacturers may respond by emphasizing advanced features-directional microphones, custom molds, and fine-tuned fitting-that remain difficult to replicate with generic earbuds.
For regulators, the De Novo authorization sets a template for how future software-based hearing aids might be evaluated. The pathway shows that the FDA is willing to treat software running on mass-market hardware as a medical device in its own right, provided there is evidence of safety and effectiveness. That could invite other tech companies to pursue similar clearances, expanding the range of OTC options available to adults with mild-to-moderate loss.
For consumers, the immediate impact is more pragmatic. Hearing help is now available in a form factor many people already own, at a price closer to mainstream electronics than to specialized medical gear. If that combination nudges even a fraction of untreated adults to address their hearing, the AirPods hearing aid feature will have altered not just a product category but the everyday experience of living with hearing loss.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
